FDA Panel Rejects Avastin for Breast Cancer
Updated: 2011-06-30 05:35:09
Health News FDA Panel Rejects Avastin for Breast Cancer Print E-mail WEDNESDAY , June 29 HealthDay News The blockbuster cancer drug Avastin got soundly rejected late Wednesday as a treatment for metastatic breast cancer by a U.S . health advisory panel that found the medication was not effective and causes dangerous side effects . By unanimous vote , the panelists rejected the drug maker's appeal of a U.S . Food and Drug Administration recommendation last December to revoke Avastin's approval for breast cancer . The FDA recommendation cited the medication's poor performance in follow-up studies and its potential for serious side . effects The drug maker , Genentech , now owned by pharmaceutical giant Roche , was given an unusual two-day hearing this week before the six-member advisory .